Crispr Therapeutics (NASDAQ:CRSP) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a report released on Wednesday, January 1st, BidAskClub reports.

A number of other research firms have also weighed in on CRSP. Roth Capital boosted their target price on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Needham & Company LLC reissued a “buy” rating and set a $84.00 target price on shares of Crispr Therapeutics in a report on Monday, December 23rd. Chardan Capital reaffirmed a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a report on Monday, November 18th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Finally, Oppenheimer upped their price objective on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $71.38.

NASDAQ CRSP opened at $60.35 on Wednesday. Crispr Therapeutics has a 52 week low of $29.34 and a 52 week high of $74.00. The stock has a market capitalization of $3.31 billion, a price-to-earnings ratio of -17.54 and a beta of 3.20. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock’s 50 day moving average price is $66.17 and its two-hundred day moving average price is $51.41.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. On average, equities research analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current year.

In other news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. Insiders own 21.40% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Nikko Asset Management Americas Inc. lifted its holdings in Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after acquiring an additional 906,006 shares during the period. Price T Rowe Associates Inc. MD increased its position in Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after buying an additional 121,176 shares during the last quarter. Wells Fargo & Company MN increased its position in Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after buying an additional 116,540 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in Crispr Therapeutics in the third quarter worth $21,167,000. Finally, Morgan Stanley increased its position in Crispr Therapeutics by 6.1% in the second quarter. Morgan Stanley now owns 284,984 shares of the company’s stock worth $13,423,000 after buying an additional 16,361 shares during the last quarter. Institutional investors and hedge funds own 49.82% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: Cryptocurrencies

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link